Sapropterin for phenylketonuria: A Japanese post‐marketing surveillance study

por Tamura, Mina, Seki, Shizuka, Kakurai, Yasuyuki, Chikada, Shuichi, Wada, Kento
Publicado 2022

A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safet...

por Inoue, Satoshi, Saito, Yoji, Tsuneto, Satoru, Aruga, Etsuko, Ide, Azusa, Kakurai, Yasuyuki
Publicado 2017

Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia

por Sekiguchi, Naohiro, Kasahara, Senji, Miyamoto, Toshihiro, Kiguchi, Toru, Ohno, Hitoshi, Takagi, Taiga, Tachibana, Masaya, Sumi, Hiroyuki, Kakurai, Yasuyuki, Yamashita, Tomonari, Usuki, Kensuke
Publicado 2022

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

por Takahashi, Shunji, Fujiwara, Yutaka, Nakano, Kenji, Shimizu, Toshio, Tomomatsu, Junichi, Koyama, Takafumi, Ogura, Mariko, Tachibana, Masaya, Kakurai, Yasuyuki, Yamashita, Tomonari, Sakajiri, Sakura, Yamamoto, Noboru
Publicado 2021

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansio...

por Shitara, Kohei, Satoh, Taroh, Iwasa, Satoru, Yamaguchi, Kensei, Muro, Kei, Komatsu, Yoshito, Nishina, Tomohiro, Esaki, Taito, Hasegawa, Jun, Kakurai, Yasuyuki, Kamiyama, Emi, Nakata, Tomoko, Nakamura, Kota, Sakaki, Hayato, Hyodo, Ichinosuke
Publicado 2019

Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma

por Kato, Koji, Makita, Shinichi, Goto, Hideki, Kanda, Junya, Fujii, Nobuharu, Shimada, Kazuyuki, Akashi, Koichi, Izutsu, Koji, Teshima, Takanori, Fukuda, Natsuko, Sumitani, Tokuhito, Sumi, Hiroyuki, Shimizu, Shinji, Kakurai, Yasuyuki, Yoshikawa, Kenji, Tobinai, Kensei, Usui, Noriko, Hatake, Kiyohiko
Publicado 2021

ACT-14 A FIRST-IN-HUMAN STUDY OF MUTANT IDH1 INHIBITOR DS-1001B IN PATIENTS WITH RECURRENT GLIOMAS

por Arakawa, Yoshiki, Mineharu, Yohei, Wakabayashi, Toshihiko, Natsume, Atsushi, Miyakita, Yasuji, Narita, Yoshitaka, Yamasaki, Fumiyuki, Sugiyama, Kazuhiko, Hata, Nobuhiro, Muragaki, Yoshihiro, Nishikawa, Ryo, Shinojima, Naoki, Kumabe, Toshihiro, Saito, Ryuta, Ito, Kazumi, Tachibana, Masaya, Kakurai, Yasuyuki, Yamaguchi, Tomoyuki, Nishijima, Soichiro, Tsubouchi, Hiroshi
Publicado 2019

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

por Izutsu, Koji, Makita, Shinichi, Nosaka, Kisato, Yoshimitsu, Makoto, Utsunomiya, Atae, Kusumoto, Shigeru, Morishima, Satoko, Tsukasaki, Kunihiro, Kawamata, Toyotaka, Ono, Takaaki, Rai, Shinya, Katsuya, Hiroo, Ishikawa, Jun, Yamada, Hironori, Kato, Kazunobu, Tachibana, Masaya, Kakurai, Yasuyuki, Adachi, Nobuaki, Tobinai, Kensei, Yonekura, Kentaro, Ishitsuka, Kenji
Publicado 2023

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

por Natsume, Atsushi, Arakawa, Yoshiki, Narita, Yoshitaka, Sugiyama, Kazuhiko, Hata, Nobuhiro, Muragaki, Yoshihiro, Shinojima, Naoki, Kumabe, Toshihiro, Saito, Ryuta, Motomura, Kazuya, Mineharu, Yohei, Miyakita, Yasuji, Yamasaki, Fumiyuki, Matsushita, Yuko, Ichimura, Koichi, Ito, Kazumi, Tachibana, Masaya, Kakurai, Yasuyuki, Okamoto, Naoko, Asahi, Takashi, Nishijima, Soichiro, Yamaguchi, Tomoyuki, Tsubouchi, Hiroshi, Nakamura, Hideo, Nishikawa, Ryo
Publicado 2022